A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: Effect on mucociliary clearance and clinical outcomes.

Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
Scott H DonaldsonStephanie D Davis

Abstract

Hypertonic saline (HS) is commonly prescribed for children with cystic fibrosis (CF) despite the absence of strong data indicating clinical efficacy in a population with mild lung disease. We hypothesized that HS treatment would result in a sustained improvement in mucociliary clearance (MCC) in children with CF who had minimal lung disease, thus providing evidence for a biologically relevant effect that also may be associated with clinical improvements. We performed a randomized, placebo controlled, double blind study of 6% versus 0.12% sodium chloride, delivered three-times daily with an eFlow nebulizer for 4 weeks. MCC was measured using gamma scintigraphy at baseline, 2-hours after the first study treatment, and ~12-hours after the final dose (at day 28). Spirometry, respiratory symptoms (CFQ-R), and safety were also assessed. Study treatments were generally well tolerated and safe. HS (6% sodium chloride) resulted in a significant, sustained improvement from baseline in whole lung clearance after 4 weeks of therapy (p = 0.014), despite absence of a prolonged single-dose effect after the initial dose. This sustained change (12 hrs after prior dose) was significantly greater when compared to placebo (0.12% sodium chloride) t...Continue Reading

References

Sep 1, 1995·American Journal of Respiratory and Critical Care Medicine
Nov 7, 2003·Journal of Pediatric Psychology·Avani C Modi, Alexandra L Quittner
Jan 20, 2006·The New England Journal of Medicine·Mark R ElkinsUNKNOWN National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group
Jan 20, 2006·The New England Journal of Medicine·Scott H DonaldsonRichard C Boucher
Jun 15, 2007·Seminars in Respiratory and Critical Care Medicine·Robert TarranRichard C Boucher
May 23, 2012·JAMA : the Journal of the American Medical Association·Margaret RosenfeldUNKNOWN ISIS Study Group
Mar 23, 2013·Journal of Aerosol Medicine and Pulmonary Drug Delivery·William D BennettScott Donaldson
Jun 8, 2013·American Journal of Respiratory and Critical Care Medicine·Padmaja SubbaraoFelix Ratjen
Apr 26, 2015·Journal of Applied Physiology·W D BennettS H Donaldson
Jan 27, 2018·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Aaron T TrimbleScott H Donaldson
Mar 31, 2018·The European Respiratory Journal·Jennifer L GoralskiBrian Button
Nov 10, 2018·American Journal of Respiratory and Critical Care Medicine·Mirjam StahlMarcus A Mall

❮ Previous
Next ❯

Citations

Nov 12, 2020·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·C ShortJ C Davies
May 1, 2021·Antibiotics·Rosa María Girón MorenoRosa Mar Gómez-Punter
Aug 8, 2021·Italian Journal of Pediatrics·Vito TerlizziDiletta Innocenti

❮ Previous
Next ❯

Related Concepts

Related Feeds

CFTR Mutant Structural Therapy

Over 1700 different mutations in the CFTR genes have been shown to cause cystic fibrosis. Here is the latest research on structural therapy for CFTR mutants.

Related Papers

Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
Aaron T TrimbleScott H Donaldson
The Annals of Pharmacotherapy
Lisa M Taylor, Robert J Kuhn
The Cochrane Database of Systematic Reviews
P A B Wark, V McDonald
© 2021 Meta ULC. All rights reserved